Pulmonary and systemic fluid filtration after continuous versus bolus interleukin-2 infusion

B. A. Harms, D. J. Rosenfeld, R. L. Conhaim, A. C. Pahl, Ramiah Subramanian, F. K. Storm

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Interleukin-2 has been widely investigated as adjuvant therapy for advanced cancer and is administered by either bolus or continuous infusion. We compared the effects of bolus and continuous interleukin-2 infusion on pulmonary (Q(L)) and systemic microvascular fluid filtration in 11 adult sheep prepared with chronic lung and soft-tissue lymph fistulas. Interleukin-2 was administered as a bolus infusion (100,000 units/kg) every 8 hours for 3 days or as a continuous infusion at the same dose for 3 days. No significant changes in pulmonary hydrostatic pressures or pulmonary vascular resistance were noted after either bolus or continuous interleukin-2 infusion. However, significantly decreased (p ≤ 0.05) systemic vascular resistances were observed in both groups. Q(L) increased steadily throughout the infusion period in both groups, peaking at three times baseline on the third infusion day. The plasma/interstitial protein clearance (Q(L) x lymph/plasma protein ratio) rose similarly in both groups, indicating increased barrier permeability. Increased lymphocyte clearance into lung lymph occurred by day 3 but was not associated with lymphocytic sequestration in the lung interstitium. We conclude that pulmonary and systemic microvascular fluid and protein flux exhibit similar changes after bolus or continuous interleukin-2 infusion. These changes are associated with increased clearance of lymphocytes into lung lymph that are not sequestered in the pulmonary interstitium after infusions of shorter duration.

Original languageEnglish (US)
Pages (from-to)500-507
Number of pages8
JournalSurgery
Volume110
Issue number3
StatePublished - Jan 1 1991

Fingerprint

Interleukin-2
Lung
Lymph
Vascular Resistance
Blood Proteins
Lymphocytes
Hydrostatic Pressure
Fistula
Permeability
Sheep
Neoplasms
Proteins

ASJC Scopus subject areas

  • Surgery

Cite this

Harms, B. A., Rosenfeld, D. J., Conhaim, R. L., Pahl, A. C., Subramanian, R., & Storm, F. K. (1991). Pulmonary and systemic fluid filtration after continuous versus bolus interleukin-2 infusion. Surgery, 110(3), 500-507.

Pulmonary and systemic fluid filtration after continuous versus bolus interleukin-2 infusion. / Harms, B. A.; Rosenfeld, D. J.; Conhaim, R. L.; Pahl, A. C.; Subramanian, Ramiah; Storm, F. K.

In: Surgery, Vol. 110, No. 3, 01.01.1991, p. 500-507.

Research output: Contribution to journalArticle

Harms, BA, Rosenfeld, DJ, Conhaim, RL, Pahl, AC, Subramanian, R & Storm, FK 1991, 'Pulmonary and systemic fluid filtration after continuous versus bolus interleukin-2 infusion', Surgery, vol. 110, no. 3, pp. 500-507.
Harms BA, Rosenfeld DJ, Conhaim RL, Pahl AC, Subramanian R, Storm FK. Pulmonary and systemic fluid filtration after continuous versus bolus interleukin-2 infusion. Surgery. 1991 Jan 1;110(3):500-507.
Harms, B. A. ; Rosenfeld, D. J. ; Conhaim, R. L. ; Pahl, A. C. ; Subramanian, Ramiah ; Storm, F. K. / Pulmonary and systemic fluid filtration after continuous versus bolus interleukin-2 infusion. In: Surgery. 1991 ; Vol. 110, No. 3. pp. 500-507.
@article{3741d176c6a44dbb93fc93df7cd9f080,
title = "Pulmonary and systemic fluid filtration after continuous versus bolus interleukin-2 infusion",
abstract = "Interleukin-2 has been widely investigated as adjuvant therapy for advanced cancer and is administered by either bolus or continuous infusion. We compared the effects of bolus and continuous interleukin-2 infusion on pulmonary (Q(L)) and systemic microvascular fluid filtration in 11 adult sheep prepared with chronic lung and soft-tissue lymph fistulas. Interleukin-2 was administered as a bolus infusion (100,000 units/kg) every 8 hours for 3 days or as a continuous infusion at the same dose for 3 days. No significant changes in pulmonary hydrostatic pressures or pulmonary vascular resistance were noted after either bolus or continuous interleukin-2 infusion. However, significantly decreased (p ≤ 0.05) systemic vascular resistances were observed in both groups. Q(L) increased steadily throughout the infusion period in both groups, peaking at three times baseline on the third infusion day. The plasma/interstitial protein clearance (Q(L) x lymph/plasma protein ratio) rose similarly in both groups, indicating increased barrier permeability. Increased lymphocyte clearance into lung lymph occurred by day 3 but was not associated with lymphocytic sequestration in the lung interstitium. We conclude that pulmonary and systemic microvascular fluid and protein flux exhibit similar changes after bolus or continuous interleukin-2 infusion. These changes are associated with increased clearance of lymphocytes into lung lymph that are not sequestered in the pulmonary interstitium after infusions of shorter duration.",
author = "Harms, {B. A.} and Rosenfeld, {D. J.} and Conhaim, {R. L.} and Pahl, {A. C.} and Ramiah Subramanian and Storm, {F. K.}",
year = "1991",
month = "1",
day = "1",
language = "English (US)",
volume = "110",
pages = "500--507",
journal = "Surgery (United States)",
issn = "0039-6060",
publisher = "Mosby Inc.",
number = "3",

}

TY - JOUR

T1 - Pulmonary and systemic fluid filtration after continuous versus bolus interleukin-2 infusion

AU - Harms, B. A.

AU - Rosenfeld, D. J.

AU - Conhaim, R. L.

AU - Pahl, A. C.

AU - Subramanian, Ramiah

AU - Storm, F. K.

PY - 1991/1/1

Y1 - 1991/1/1

N2 - Interleukin-2 has been widely investigated as adjuvant therapy for advanced cancer and is administered by either bolus or continuous infusion. We compared the effects of bolus and continuous interleukin-2 infusion on pulmonary (Q(L)) and systemic microvascular fluid filtration in 11 adult sheep prepared with chronic lung and soft-tissue lymph fistulas. Interleukin-2 was administered as a bolus infusion (100,000 units/kg) every 8 hours for 3 days or as a continuous infusion at the same dose for 3 days. No significant changes in pulmonary hydrostatic pressures or pulmonary vascular resistance were noted after either bolus or continuous interleukin-2 infusion. However, significantly decreased (p ≤ 0.05) systemic vascular resistances were observed in both groups. Q(L) increased steadily throughout the infusion period in both groups, peaking at three times baseline on the third infusion day. The plasma/interstitial protein clearance (Q(L) x lymph/plasma protein ratio) rose similarly in both groups, indicating increased barrier permeability. Increased lymphocyte clearance into lung lymph occurred by day 3 but was not associated with lymphocytic sequestration in the lung interstitium. We conclude that pulmonary and systemic microvascular fluid and protein flux exhibit similar changes after bolus or continuous interleukin-2 infusion. These changes are associated with increased clearance of lymphocytes into lung lymph that are not sequestered in the pulmonary interstitium after infusions of shorter duration.

AB - Interleukin-2 has been widely investigated as adjuvant therapy for advanced cancer and is administered by either bolus or continuous infusion. We compared the effects of bolus and continuous interleukin-2 infusion on pulmonary (Q(L)) and systemic microvascular fluid filtration in 11 adult sheep prepared with chronic lung and soft-tissue lymph fistulas. Interleukin-2 was administered as a bolus infusion (100,000 units/kg) every 8 hours for 3 days or as a continuous infusion at the same dose for 3 days. No significant changes in pulmonary hydrostatic pressures or pulmonary vascular resistance were noted after either bolus or continuous interleukin-2 infusion. However, significantly decreased (p ≤ 0.05) systemic vascular resistances were observed in both groups. Q(L) increased steadily throughout the infusion period in both groups, peaking at three times baseline on the third infusion day. The plasma/interstitial protein clearance (Q(L) x lymph/plasma protein ratio) rose similarly in both groups, indicating increased barrier permeability. Increased lymphocyte clearance into lung lymph occurred by day 3 but was not associated with lymphocytic sequestration in the lung interstitium. We conclude that pulmonary and systemic microvascular fluid and protein flux exhibit similar changes after bolus or continuous interleukin-2 infusion. These changes are associated with increased clearance of lymphocytes into lung lymph that are not sequestered in the pulmonary interstitium after infusions of shorter duration.

UR - http://www.scopus.com/inward/record.url?scp=0025776816&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025776816&partnerID=8YFLogxK

M3 - Article

C2 - 1887373

AN - SCOPUS:0025776816

VL - 110

SP - 500

EP - 507

JO - Surgery (United States)

JF - Surgery (United States)

SN - 0039-6060

IS - 3

ER -